Abarelix (Plenaxis) for Advanced Prostate Cancer
Abarelix (Plenaxis - Praecis Pharmaceuticals), an injectable gonadotropin-releasing hormone (GnRH) antagonist, has been approved by the FDA for treatment of advanced symptomatic prostate cancer in patients who should not take luteinizing hormone-releasing hormone (LHRH) agonists and who refuse treatment with surgical castration....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Abarelix (Plenaxis) for Advanced Prostate Cancer
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1178
Article Code: 1178b
Date: March 15, 2004
Volume: 46
Pages: 22-23
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1178
Article Code: 1178b
Date: March 15, 2004
Volume: 46
Pages: 22-23
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)